Fig. 4

The HRD-DNA and HRD-RNA models are enriched for a HRD-phenotype and are concordant with published HRD+ rates. A Enrichment for HRD+ calls in samples with biallelic loss of HRR genes for breast cancer and ovarian cancer (HRD-DNA), and other cancers (HRD-RNA). Enrichment was calculated using a Fisher’s exact test comparing samples from the HRD-ambiguous and HR-WT samples that has biallelic loss of specific HRR gene versus all other samples. Significance was determined as p-value < 0.05. B Distribution of GWLOH percentage (top) and HRD-RNA scores (bottom) of breast cancer samples with BRCA1/2 reversion mutations. Significance shown for two-sided Wilcoxon-test. C Predicted rates of HRD+ samples across cancer types compared to published rates (CHORD), stratified by primary and metastatic samples. For breast and ovarian cancer, the HRD-DNA model was used to determine rates of HRD+ samples. For all other cancer cohorts, the HRD-RNA model was used